Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

Critical reviews in oncology/hematology - 1 Apr 2001

Kashmiri S V, Iwahashi M, Tamura M, Padlan E A, Milenic D E, Schlom J

Abstract excerpt

Monoclonal antibody (MAb) CC49 reacts with a pancarcinoma antigen, tumor associated glycoprotein (TAG)-72. To circumvent human anti-murine antibody (HAMA) responses in patients, we earlier developed a humanized CC49 (HuCC49) by grafting the complementarity-determining regions (CDRs) of MAb CC49 onto variable light (VL) and variable heavy (VH) frameworks of the human MAbs LEN and 21/28'CL, respectively. With the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Complementarity Determining Regions

Share to Drug Design

Share to Genetic Engineering

Share to Genetic Variation

Share to Neoplasms

Source

Identifiers

PMID: 11255077
DOI: 10.1016/s1040-8428(00)00133-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.PMID 11255077Read ↗

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.Semantic proximity Read ↗

Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-tag-72 single-chain FvsSemantic proximity Read ↗

Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.Semantic proximity Read ↗

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.Semantic proximity Read ↗

Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen.Semantic proximity Read ↗

Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple MethodSemantic proximity Read ↗

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.Semantic proximity Read ↗

Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.Semantic proximity Read ↗

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.Semantic proximity Read ↗

“Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28Semantic proximity Read ↗

Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformationSemantic proximity Read ↗

Preparation and characterization of a chimeric CD 19 monoclonal antibodySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.